XBIO Stock Overview
A biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Xenetic Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.15 |
| 52 Week High | US$5.20 |
| 52 Week Low | US$2.78 |
| Beta | 2.24 |
| 1 Month Change | 0.97% |
| 3 Month Change | 8.92% |
| 1 Year Change | 14.96% |
| 3 Year Change | -68.80% |
| 5 Year Change | -70.36% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Shareholder Returns
| XBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | -3.3% | -0.4% |
| 1Y | 15.0% | -2.7% | 24.8% |
Return vs Industry: XBIO exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: XBIO underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| XBIO volatility | |
|---|---|
| XBIO Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XBIO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Jim Parslow | www.xeneticbio.com |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors.
Xenetic Biosciences, Inc. Fundamentals Summary
| XBIO fundamental statistics | |
|---|---|
| Market cap | US$6.40m |
| Earnings (TTM) | -US$4.08m |
| Revenue (TTM) | US$2.52m |
2.5x
P/S Ratio-1.6x
P/E RatioIs XBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBIO income statement (TTM) | |
|---|---|
| Revenue | US$2.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.52m |
| Other Expenses | US$6.60m |
| Earnings | -US$4.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | -161.58% |
| Debt/Equity Ratio | 0% |
How did XBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:24 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xenetic Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Kevin DeGeeter | Ladenburg Thalmann & Company |
| Rahul Jasuja | NOBLE Capital Markets, Inc. |